Manager TitleAgeSince
Director of Finance/CFO 56 01/01/2023
Comptroller/Controller/Auditor - -
Corporate Officer/Principal 61 01/01/2020
Director TitleAgeSince
Chairman 69 01/09/2026
Director/Board Member 56 01/01/2020
Director/Board Member 54 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-44.44%-44.44% - - 97.91K
+2.68%+3.87%+58.22%+114.68% 1,026B
+0.56%+1.27%+53.29%+68.65% 649B
+0.02%+0.99%+19.10%+73.58% 468B
+0.06%+0.25%+37.03%+45.71% 352B
+1.16%+4.10%+21.99%+29.39% 271B
-0.24%+2.18%+10.14%+12.26% 256B
-0.01%+7.89%+41.57%+51.68% 220B
-1.11%+1.36%+30.85%+99.56% 188B
+0.30%-7.19%-32.43%-60.56% 170B
Average -4.00%+1.26%+26.64%+48.33% 399.9B
Weighted average by Cap. +1.08%+1.26%+37.30%+67.68%
Logo Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
Employees
5
  1. Stock Market
  2. Stocks
  3. LPGO Stock